Intravitreal Tissue Plasminogen Activator with C3F8 Injection in Branch Retinal Vein Occlusion.
10.3341/jkos.2008.49.3.450
- Author:
Ji Won LIM
1
;
Jung Hoon CHOI
;
In Won PARK
Author Information
1. Department of Ophthalmology, Hallym University Sacred Heart Hospital, Gyeonggi, Korea. piw@korea.com
- Publication Type:Original Article
- Keywords:
Branch retinal vein occlusion;
Intravitreal injection;
Tissue plasminogen activator
- MeSH:
Hemorrhage;
Humans;
Intravitreal Injections;
Macular Edema;
Retinal Vein;
Retinal Vein Occlusion;
Retinaldehyde;
Tissue Plasminogen Activator;
Tomography, Optical Coherence;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2008;49(3):450-455
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the efficacy of intravitreal tissue plasminogen activator (tPA) with C3F8 injection for branch retinal vein occlusion (BRVO) involving fovea. METHODS: Seven patients (7 eyes) presenting with subfoveal hemorrhage caused by BRVO were treated with an intravitreal tPA and C3F8 injection. We assessed the visual acuity (VA) and foveal thickness measured with optical coherence tomography. RESULTS: The mean duration of symptoms before surgery was 5.42+/-1.90 weeks. The mean logMAR VA improved from 1.14+/-0.19 at baseline to 0.87+/-0.34 at one week and 0.30+/-0.32 at six months. The mean foveal thickness decreased from 564.421+/-186.88 micrometer at baseline to 483.14+/-275.06 micrometer at one week and 353.28+/-152.99 micrometer at six months. There was no adverse effect related to the treatment. CONCLUSIONS: Intravitreal tPA with C3F8 injection may be an effective treatment for resolving macular edema with subfoveal hemorrhage and improving the VA in recently developed BRVO.
